https://doi.org/10.55788/82f1afbb
The study enrolled 4,497 patients who underwent cholecystectomy for acute cholecystitis at a South Korean hospital [1]. The primary goal was to evaluate gallstones as a risk factor for developing GBP. The findings were presented by Dr Se Woo Park (Hallym University Dongtan Sacred Heart Hospital, South Korea) [2].
The results showed that the incidence of GBP was significantly higher in the acalculous cholecystitis group compared with the calculous cholecystitis group (5.6% vs 1%; P<0.001). Despite similar durations of intensive care unit admissions and hospital stays between the 2 groups, the incidence of post-operative complications was significantly higher in the acalculous cholecystitis group than in the calculous cholecystitis group (2.2% vs 1%; P<0.001). The multivariable analysis confirmed that patients with acalculous cholecystitis had a higher risk of developing GBP than those with calculous cholecystitis (OR 5.0; 95% CI 2.94â8.33).
Older age (â„60 years) (OR 5.0; 95% CI 1.49â4.63), male sex (OR 2.55; 95% CI 1.48â4.57), and coexisting acute cholangitis (OR 2.84; 95% CI 1.71â4.80) were additional factors associated with the development of GBP. The incidence of GBP was significantly higher in patients who underwent delayed cholecystectomy compared with those who had early surgery (2% vs 0.9%; P<0.001).
Overall, this study suggests that acalculous cholecystitis is a risk factor for GBP, while the presence of gallstones has a relatively minor influence on GBP. âEarly cholecystectomy can significantly reduce GBP morbidity and mortality. The incidence of GBP is relatively low, but its implications are very serious, warranting a high degree of suspicion, especially in higher-risk patients, such as those with acalculous cholecystitis,â concluded Dr Park.
- Lee KJ, et al. Int J Surg. 2024;110(3):1383-1391.
- Park SW, et al. Gallblader perforation in acute acalculous vs. calculous cholecystitis: a retrospective comparative cohort study with 10-year single-center experience. 329, DDW 2024, 18â21 May, Washington, DC, USA.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« STARS: Apraglutide shows efficacy in short bowel syndrome with intestinal failure Next Article
REGENERATE study: Obeticholic acid shows antifibrotic benefit in NASH »
« STARS: Apraglutide shows efficacy in short bowel syndrome with intestinal failure Next Article
REGENERATE study: Obeticholic acid shows antifibrotic benefit in NASH »
Table of Contents: DDW 2024
Featured articles
PREEMPT CRC: Blood-based screening test for colorectal cancer shows promise
Eosinophilic Oesophagitis Treatments and Outcomes
Mepolizumab improves the histologic severity of eosinophilic oesophagitis
Budesonide demonstrates efficacy in eosinophilic oesophagitis
Dupilumab shows promising results in treating paediatric eosinophilic oesophagitis
Quality-of-life assessment in children with eosinophilic oesophagitis
Gut-Brain Axis and Neurological Disorders
Gut permeability and neuroinflammation linked in Parkinsonâs disease
Cardiovascular and Metabolic Health Innovations
Promising data for cardiovascular outcomes of bariatric surgery in patients with obesity
Inflammatory Bowel Disease Therapies
GALAXI 2 & 3: Guselkumab proves efficacy in Crohnâs disease
QUASAR maintenance study: Guselkumab effective and safe for UC
VEDOKIDS: Vedolizumab maintains remission in patients with paediatric IBD
ADMIRE-CD II: Darvadstrocel does not meet primary endpoint in complex Crohnâs perianal fistulas
Advances in Endoscopy and Screening Techniques
PREEMPT CRC: Blood-based screening test for colorectal cancer shows promise
New cable-transmission capsule endoscopy shows high accuracy in detecting upper GI lesions
Liver and Biliary Tract Diseases Updates
Superior OS with atezolizumab plus bevacizumab versus lenvatinib in unresectable HCC
Nutritional consultation boosts nutritional status in patients with alcohol-associated hepatitis
REGENERATE study: Obeticholic acid shows antifibrotic benefit in NASH
Acalculous cholecystitis as a risk factor for gallbladder perforation: insights from a 10-year retrospective study
Other Gastrointestinal Diseases
STARS: Apraglutide shows efficacy in short bowel syndrome with intestinal failure
COX-2 inhibitors show promise in reducing severity of acute pancreatitis
Hormone-containing therapies may increase the risk of IBS and functional dyspepsia
Related Articles
November 28, 2024
Tradipitant improves symptoms of motion sickness
November 2, 2020
Sustained response to faecal microbiota transplantation
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com